Title: Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Authors: Coles, Alasdair J ×
Twyman, Cary L
Arnold, Douglas L
Cohen, Jeffrey A
Confavreux, Christian
Fox, Edward J
Hartung, Hans-Peter
Havrdova, Eva
Selmaj, Krzysztof W
Weiner, Howard L
Miller, Tamara
Fisher, Elizabeth
Sandbrink, Rupert
Lake, Stephen L
Margolin, David H
Oyuela, Pedro
Panzara, Michael A
Compston, D Alastair S
CARE-MS II investigators #
Contributors: Dubois, Bénédicte
Issue Date: Nov-2012
Publisher: The Lancet Publishing Group
Series Title: The Lancet vol:380 issue:9856 pages:1829-39
Article number: 10.1016/S0140-6736(12)61768-1
Abstract: The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.
ISSN: 0140-6736
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Non-KU Leuven Association publications
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science